Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: Avoiding a serious adverse drug interaction

Mycoses

Volumn 54, Issue 6, 2011, Pages

  Moriyama, Brad ^a   Falade Nwulia, Oluwaseun ^a   Leung, Janice ^a   Penzak, Scott R ^a   Jjingo, Caroline ^b   Huang, Xuan ^c   Henning, Stacey A ^a   Wilson, Wyndham H ^c   Walsh, Thomas J ^d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2C19; DOXORUBICIN; ETOPOSIDE; PREDNISONE; VINCRISTINE; VORICONAZOLE;

ADD ON THERAPY; ADULT; AREA UNDER THE CURVE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHRONIC KIDNEY FAILURE; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEMOPHAGOCYTIC SYNDROME; HUMAN; LETTER; LUNG LAVAGE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; NONHUMAN; OBESITY; PASTEURELLOSIS; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; SEPTIC SHOCK;

ADULT; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; DRUG INTERACTIONS; GENOTYPE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; PYRIMIDINES; TRIAZOLES; VINCRISTINE;

EID: 80955179996     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02016.x     Document Type: Letter

References (0)